Data as of Nov 21
| +0.36 / +1.94%|
The 6 analysts offering 12-month price forecasts for Neurocrine Biosciences Inc have a median target of 23.00, with a high estimate of 26.00 and a low estimate of 20.00. The median estimate represents a +21.37% increase from the last price of 18.95.
The current consensus among 7 polled investment analysts is to Buy stock in Neurocrine Biosciences Inc. This rating has held steady since November, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.